These Analysts Revise Their Forecasts On Repligen Following Q2 Results

Comments
Loading...

Repligen Corporation RGEN reported in-line earnings for its second quarter on Tuesday.

The company posted second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. The company reported an adjusted EPS of 33 cents, which is in line with the consensus but below $0.53 reported a year ago.

Tony J. Hunt, CEO of Repligen, said, "We delivered solid second-quarter revenue of $154 million and first-half revenue of $305 million, achieving our year-to-date sales target. We are very encouraged by orders in the quarter, with continued strength in Pharma demand and a pickup in CDMO activity. New modalities continued to show strong year-over-year momentum in both revenue and orders."

Repligen expects 2024 revenues of $620 million—$635 million, compared to prior guidance of $620 million—$650 million and the consensus of $636.6 million.

Repligen shares gained 5.3% to trade at $169.16 on Wednesday.

These analysts made changes to their price targets on Repligen following earnings announcement.

Read More:

RGEN Logo
RGENRepligen Corp
$143.80-5.90%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum35.89
Growth42.29
Quality-
Value15.54
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: